Kristine Peterson - 19 Oct 2026 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Director
Issuer ticker: MLYS
Reported as of: 19 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Oct 2026, 17:35:00 UTC
Prior SEC filing: 22 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey A. Munsie, attorney-in-fact

Filing notes and source

Key filing fact

Kristine Peterson filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 20 Oct 2026.

Key facts

This page summarizes Kristine Peterson's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Oct 2026, 17:35.

Change

Previous filing in this sequence was filed on 22 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001508596 Primary reporting owner

Peterson Kristine

Relationship: Director
Address: C/O MINERALYS THERAPEUTICS, INC., 150 N. RADNOR CHESTER ROAD, SUITE F200, RADNOR
Signature: /s/ Jeffrey A. Munsie, attorney-in-fact
Signature date: 20 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Award

Transaction value
Shares: +12,400
Change %
Price: $0.000000^*
Shares after: 12,400
Date: 19 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Award

Transaction value
Shares: +16,600
Change %
Price: $0.000000^*
Shares after: 16,600
Date: 19 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,600
Exercise price: $20.92
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of restricted stock units (RSUs) granted for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of three years, with 1/3rd of the RSUs vesting on each one-year anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.

Footnote F2

The shares underlying the stock option vest in monthly installments over a period of three years, with 1/36th of the underlying shares vesting on each monthly anniversary of the grant date, subject to the reporting person's continued service through each applicable vesting date.